GBC Blog

Epigenomics Initiates €5.5M Private Placement Sep 21, 2017, NEW YORK (GenomeWeb) – Epigenomics said today that it plans to raise approximately €5.5 million ($6.5 million) in a private share placement. The Berlin-based molecular diagnostic firm said that it will increase its share capital in the amount of €1.28 by issuing approximately 1.28 million new registered shares…

BioreclamationIVT has acquired Asterand Bioscience™, a global provider of human tissue and research solutions with a focus on the oncology market. Asterand Bioscience advances drug research by accelerating target identification and biomarker validation, and improving drug candidate selection to increase the likelihood of clinical success. “We are delighted that Asterand Bioscience’s talented staff is joining…

DETROIT & ROYSTON, U.K., July 11, 2017 /EINPresswire.com/ — Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research solutions supporting drug discovery and development, announced today the introduction of the PerkinElmer Vectra® Polaris™ Automated Quantitative Pathology Imaging System to extend their services capabilities to support scientists in gaining a deeper understanding…

Recent Data on Curetis’ Unyvero ITI Application Demonstrate its Clinical and Health Economic Benefits – Several ECCMID 2017 presentations highlight advantages of rapid time to result with Unyvero ITI in Prosthetic Joint Infections Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 27, 2017 – Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer…

Epigenomics Agrees to Takeover Bid Apr 26, 2017  NEW YORK (GenomeWeb) – German molecular diagnostics firm Epigenomics announced today that it has agreed to a public takeover offer from Blitz F16-83, a subsidiary of Chinese private equity firm Cathay Fortune International. Under the terms of the deal, Epigenomics shareholders will be offered €7.52 ($8.19) in…

Curetis’ Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking – Product to launch in EMEA at ECCMID Conference April 22-25, 2017 – IAI Panel covers up to 130 diagnostic targets Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 20, 2017 – Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular…

Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe – U.S. data set complemented by recent clinical study data from European hospital Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 10, 2017 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today…

  FDA Approves 23andMe’s Genetic Test for Personal Disease Risks – Agency stresses that product labeling should show test not designed to diagnose, determine treatment or say anything about user’s state of health Wall Street Journal, April 6, 2017 5:47 p.m. ET Food and Drug Administration approved the first-ever direct-to-consumer genetic testing for people’s personal…

Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing – Successful completion of GEAR asset and know how transfer from Siemens to Curetis Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 6, 2017 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that…

Computational Biologists Predict Antibiotic Resistances Using Biotech March 10, 2017 06:47 ET | Source: Curetis GmbH Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for…